| Outcome Measures: |
Primary: Change from baseline to week 24 in LDL-C level, Baseline, Week 24 | Secondary: Change from baseline to week 12 in LDL-C level, Baseline, Week 12|Change from baseline to week 12 and week 24 in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), Baseline, Week 12, Week 24|Change from baseline to week 12 and week 24 in high-sensitivity C-reactive protein (hs-CRP), Baseline, Week 12, Week 24|Change from baseline to week 12 and week 24 in Apolipoprotein A1, Apolipoprotein B, Apolipoprotein B48, and Apolipoprotein B/Apolipoprotein A1, Baseline, Week 24|Change from baseline to week 12 and week 24 in glycosylated hemoglobin (HbA1c), Baseline, Week 12, Week 24|Change from baseline to week 12 and week 24 in fasting plasma glucose (FPG), Baseline, Week 12, Week 24|Change from baseline to week 12 and week 24 in homeostasis model assessment for insulin resistance (HOMA-IR), Baseline, Week 12, Week 24|Proportion of subjects achieving LDL-C < 70mg/dL, Baseline, Week 12, Week 24|Proportion of subjects achieving LDL-C < 55mg/dL, Baseline, Week 12, Week 24|Occurrence of MACCE (Major Adverse Cardiovascular and Cerebrovascular Event), Up to 24 weeks
|
